Olema Pharmaceuticals faced a 30% stock drop after ESMO 2025 data on palazestrant, its lead breast cancer candidate. Click ...

Teva Pharmaceutical Industries Ltd. (TEVA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most ...

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands ...

Commission approves acquisition of JB Chemicals & Pharmaceuticals Ltd by Torrent Pharmaceuticals Ltd with voluntary ...

It might look like this beaten-down AI-focused company is finally bouncing back, but don't be too quick to pull the trigger.

From Ramesh Damani to Atul Suri; Dipan Mehta to Nilesh Shah; Dharmesh Kant to Deven Choksey, here's what these market experts ...

​This partnership builds on an earlier collaboration, which was launched between the two companies in 2022. As part of this ...

Recently, there have been concerns around the surge of fraudulent loans and private credit quality issues in the US.

An investigational treatment, used in combination with another cancer medication, took an important step forward after ...

Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, recently sold a significant chunk of his company's common stock. The CEO of Recursion Pharmaceuticals recently disposed of 120 ...

Rani Therapeutics secured a $1.085 billion collaboration with Chugai Pharmaceutical. Check out why I am initiating with a Buy ...